dupilumab
Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025
Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines
Dupixent (Dupilumab) Shows Promising Results in Treating Bullous Pemphigoid, Paving Way for Regulatory Submissions
Dupixent, Dupilumab, Bullous Pemphigoid, Autoimmune Disease, Biologic Treatment, Type 2 Inflammation
FDA Delays Dupixent Decision for Uncontrolled COPD Treatment, EU Panel Recommends Approval
Dupixent, dupilumab, COPD, FDA, EU approval, Sanofi, Regeneron, uncontrolled COPD, treatment delay